ProKidney Statistics
Total Valuation
ProKidney has a market cap or net worth of $729.82 million. The enterprise value is $439.51 million.
Important Dates
The next estimated earnings date is Tuesday, November 11, 2025, before market open.
| Earnings Date | Nov 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ProKidney has 294.28 million shares outstanding. The number of shares has increased by 102.08% in one year.
| Current Share Class | 134.99M |
| Shares Outstanding | 294.28M |
| Shares Change (YoY) | +102.08% |
| Shares Change (QoQ) | +1.36% |
| Owned by Insiders (%) | 18.67% |
| Owned by Institutions (%) | 16.76% |
| Float | 86.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,384.86 |
| Forward PS | n/a |
| PB Ratio | 2.15 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 833.99 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.48, with a Debt / Equity ratio of 0.01.
| Current Ratio | 11.48 |
| Quick Ratio | 10.49 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -35,263.40 |
Financial Efficiency
Return on equity (ROE) is -40.51% and return on invested capital (ROIC) is -26.78%.
| Return on Equity (ROE) | -40.51% |
| Return on Assets (ROA) | -25.30% |
| Return on Invested Capital (ROIC) | -26.78% |
| Return on Capital Employed (ROCE) | -51.27% |
| Revenue Per Employee | $2,583 |
| Profits Per Employee | -$355,265 |
| Employee Count | 204 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ProKidney has paid $799,000 in taxes.
| Income Tax | 799,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +3.33% in the last 52 weeks. The beta is 1.79, so ProKidney's price volatility has been higher than the market average.
| Beta (5Y) | 1.79 |
| 52-Week Price Change | +3.33% |
| 50-Day Moving Average | 2.76 |
| 200-Day Moving Average | 1.59 |
| Relative Strength Index (RSI) | 50.97 |
| Average Volume (20 Days) | 2,417,337 |
Short Selling Information
The latest short interest is 8.38 million, so 2.85% of the outstanding shares have been sold short.
| Short Interest | 8.38M |
| Short Previous Month | 8.69M |
| Short % of Shares Out | 2.85% |
| Short % of Float | 9.67% |
| Short Ratio (days to cover) | 3.72 |
Income Statement
In the last 12 months, ProKidney had revenue of $527,000 and -$72.47 million in losses. Loss per share was -$0.56.
| Revenue | 527,000 |
| Gross Profit | 527,000 |
| Operating Income | -176.32M |
| Pretax Income | -34.94M |
| Net Income | -72.47M |
| EBITDA | -170.19M |
| EBIT | -176.32M |
| Loss Per Share | -$0.56 |
Full Income StatementBalance Sheet
The company has $294.73 million in cash and $4.42 million in debt, giving a net cash position of $290.31 million or $0.99 per share.
| Cash & Cash Equivalents | 294.73M |
| Total Debt | 4.42M |
| Net Cash | 290.31M |
| Net Cash Per Share | $0.99 |
| Equity (Book Value) | 339.45M |
| Book Value Per Share | -7.51 |
| Working Capital | 296.18M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$114.42 million and capital expenditures -$32.16 million, giving a free cash flow of -$146.58 million.
| Operating Cash Flow | -114.42M |
| Capital Expenditures | -32.16M |
| Free Cash Flow | -146.58M |
| FCF Per Share | -$0.50 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -33,456.74% |
| Pretax Margin | -31,053.89% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ProKidney does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -102.08% |
| Shareholder Yield | -102.08% |
| Earnings Yield | -9.93% |
| FCF Yield | -20.08% |
Dividend DetailsAnalyst Forecast
The average price target for ProKidney is $6.25, which is 152.02% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.25 |
| Price Target Difference | 152.02% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 440.09% |
| EPS Growth Forecast (5Y) | -12.74% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ProKidney has an Altman Z-Score of -1.62. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.62 |
| Piotroski F-Score | n/a |
